SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors anticipate upcoming earnings and potential hyperscaler announcements, crucial for the company's AI infrastructure growth. Community discussions revolve around the timing of a new lease and the impact of Macquarie's recent funding draw. Bullish sentiment remains high due to the expected increase in AI data center demand and APLD's strategic position.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ (LAES) is trending due to a strategic partnership to develop 'Made in US' post-quantum cryptography solutions for US government and defense, sparking bullish sentiment. The community is actively discussing the potential for a short squeeze and significant upside, drawing comparisons to other quantum stocks. With high trading volume and positive news, investors are optimistic about the company's future growth and potential double-digit price targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending due to recent AI partnerships, sparking investor excitement about its potential in the agentic AI space; some view it as undervalued compared to competitors like $PLTR. The community is discussing its strategic shift from RPA to AI-driven automation and whether it can sustain growth, while others are eyeing potential short squeezes.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices approach multi-decade highs, sparking discussions about a potential breakout. Community members are debating whether demand is crushing short positions and anticipating further gains, with some pointing to a possible short squeeze. The broader context involves rising interest in precious metals as a hedge against economic uncertainty, amplified by a potentially weaker dollar and a possible government shutdown.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf ($WULF) is trending as investors discuss a potential short squeeze, fueled by its high short interest and growing optimism around its transition to AI and high-performance computing. Community members are pointing to the stock's setup mirroring past breakouts, while also highlighting analyst price targets and the increasing open interest in call options. Some are closely watching for news regarding the Lake Cayuga site approval, which could act as a further catalyst.

TOSHI

TOSHI is trending as the community rallies behind the token, pointing to strong chart patterns and increasing volume. Many are drawing comparisons to previous meme coin surges, speculating on potential listings on major exchanges like Robinhood and Binance. The community emphasizes its strong organic growth and active engagement.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense & Security Solutions is trending amid discussions about defense spending, potential contract wins, and comparisons to other high-growth tech and defense companies. The community is actively debating its valuation, potential for acquisitions, and upcoming catalysts like government contracts and drone technology advancements. Some traders are taking profits after a significant run-up, while others see it as a long-term growth play.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending amid discussions around its valuation, potential for a short squeeze, and a recent healthcare partnership with OneMedNet; the community is debating whether the stock is overvalued and if it can sustain its high growth, while some point to the potential for breakout traders to drive the price higher. Bullish sentiment remains strong despite some concerns about the company's valuation and the sustainability of its growth.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending as investors discuss its growth potential in the autonomous delivery market, especially following recent acquisitions and partnerships with major platforms like DoorDash and Uber Eats. Community members are weighing the stock's valuation and future prospects, noting the high short interest and potential for a squeeze. Bullish sentiment is fueled by expectations of revenue growth and expansion into new markets, although some caution against potential pullbacks.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as investors actively discuss the potential impact of data center constraints and new partnerships on the company's growth. Community members are speculating about upcoming news and potential deals, particularly related to its stake in Clickhouse and its role in AI infrastructure. The stock's volatility and potential for significant gains are also prominent talking points.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enanta Pharmaceuticals (ENTA) on Monday announced that its mid-stage trial evaluating the efficacy and safety of Zelicapavir in outpatient adults with acute Respiratory Syncytial Virus (RSV) infection who are at high risk of complications failed to meet the primary endpoint.Shares of the company, however, rose 58% by Monday afternoon. Notably, the company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-reports-positive-topline-results-its">stated</a> that a clinically meaningful improvement in time to complete resolution of all 13 RSV symptoms was observed for Zelicapavir compared to placebo, with a benefit of 2.2 days for the overall efficacy population and 6.7 days for patients with congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), or aged 75 and older.A lower hospitalization rate was observed for patients treated with Zelicapavir compared to placebo, and Zelicapavir demonstrated a robust antiviral effect, it added.The study, however, failed in its primary endpoint of lowering the time to resolution of lower respiratory tract disease symptoms to mild. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ENTA">ENTA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_29_at_1_22_50_PM_png_995d6b1542.webp" alt="ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits" width="576" height="65"><figcaption>ENTA's Sentiment Meter and Message Volume as of 1:23 p.m. ET on Sept. 29, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user cheered the rally.<stembedurl>https://stocktwits.com/JL_TradeZ/message/630342393</stembedurl>Another noted that though the trial missed the primary endpoint, the rest of the data “looks great.”<stembedurl>https://stocktwits.com/heyupikachu1821/message/630357384</stembedurl>Enanta said on Monday that Zelicapavir demonstrated a favorable safety profile in the trial and was well-tolerated. The goal of the study was to inform the design of a late-stage trial, including populations and endpoints, and no adverse events led to treatment discontinuation or study withdrawal in the Zelicapavir group.“We believe the totality of these data provides strong rationale for further clinical advancement of zelicapavir. Importantly, we identified multiple potential registrational endpoints for a Phase 3 trial,” said Chief Medical Officer Scott T. Rottinghaus.RSV is a common respiratory virus that infects the lungs and respiratory tract. Older adults are at significantly increased risk of severe illness due to the natural weakening of the immune system with age.ENTA stock has more than doubled this year and gained by about 20% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kala-bio-stock-plunges-after-experimental-drug-fails-study/chDuP3wR3Ja">Kala Bio Stock Just Plunged 89% Today – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, capsules are seen in a hand dressed in a medical glove with the Enanta Pharmaceuticals logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.

Equity

The company reported that a lower hospitalization rate was observed in patients treated with Zelicapavir compared to those treated with placebo, and the drug demonstrated a robust antiviral effect.


Larimar Therapeutics, Inc. (LRMR) on Monday announced positive data from an ongoing long-term open-label study evaluating daily subcutaneous injections of Nomlabofusp in participants with Friedreich’s Ataxia.Friedreich's Ataxia (FA) is a rare, inherited disorder causing progressive damage to the nervous system, leading to symptoms like poor coordination, difficulty walking, and sensory loss, as well as heart disease and scoliosis. It is caused by a mutation in the FXN gene, resulting in a deficiency of the mitochondrial protein frataxin.In the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/29/3157570/0/en/Larimar-Therapeutics-Announces-Positive-Data-from-Ongoing-Long-term-Open-Label-Study-and-Updates-to-Nomlabofusp-Program-for-Friedreich-s-Ataxia.html">study,</a> an increase in skin frataxin (FXN) levels was observed with short- and long-term daily Nomlabofusp. All ten participants with data at six months achieved skin FXN levels over 50% of median levels in healthy volunteers, the company stated. It added that consistent directional improvement across multiple clinical outcomes was also observed after a year of Nomlabofusp treatment.“These new data, as well as the improvement in abnormal lipid profiles observed in prior completed studies, provide support that nomlabofusp increases FXN in patients with FA and that the strategy of FXN replacement has the potential to result in a clinical benefit,” said CEO Carole Ben-Maimon.Shares of the company tumbled 47% in the pre-market session after the company reported that anaphylaxis, or a severe allergic reaction, was observed in seven participants in the open-label study, and they were subsequently withdrawn from the study. Most instances of anaphylaxis occurred on the initial day of administration and most within the first six weeks of dosing, it noted.Other discontinuations in the study included three cases of generalized urticaria, one seizure, one vasovagal event, and two non-treatment-related discontinuations, it said.The company said that it consulted experts and decided to modify its starting dose regimen after the two most recent cases of anaphylaxis. The U.S. Food and Drug Administration has agreed with the approach, the company said. Larimar is looking to submit an application for approval of Nomlabofusp to the FDA in the second quarter of 2026.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/LRMR">LRMR stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.LRMR stock is down by 2% this year and by 42% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/pharma-lobby-announces-new-website-to-connect-patients-with-manufacturer-direct-patient-programs/chDuciYR3JJ">Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Programs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Larimar Therapeutics Stock Slumps Pre-market Over High Anaphylaxis Rate In Drug Study

The company said that anaphylaxis or a severe allergic reaction was reported in seven participants in the open-label study evaluating Nomlabofusp in participants with Friedreich’s ataxia. 

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Shares of Rambus, Inc. (<a class="mention" data-mention="$RMBS" data-symbol-id="RMBS" href="https://stocktwits.com/symbol/RMBS" target="_blank">$RMBS</a>), a provider of Double Data Rate (DDR) memory interface chips, rose sharply early Tuesday, thanks to a positive analyst action.In a note published late-Tuesday, Baird analyst Tristan Gerra initiated coverage of Rambus with an&nbsp;‘Outperform’ rating and a $90 price target, which suggests scope for about 58% upside potential.The analyst noted that Rambus’ technology and IP is central to the artificial intelligence (AI)-driven performance increase in data centers. "Rambus is at the center of our 2025 semiconductor investment themes, which include AI memory, processors and optical systems," he said.&nbsp;Rambus has over 75% revenue exposure to data centers with AI becoming a major component of growth, Gerra said.&nbsp;He noted that the company is first to market with the October announcement of the "industry-first complete memory interface chipset for Gen 5 DDR5 RDIMM and next-generation MRDIMM." These bring much higher data transfer rates, lower latency and power consumption, he added.With the lineup, the company is poised to see a significant total addressable market expansion opportunity, Gerra said.The analyst sees major license deals with leading AI chip makers into the next year due to the HBM4 controller IP it announced in September that is expected to ramp in 2026.&nbsp;Rambus is poised to see significant growth, content increase, and share gains ahead, Baird said, adding that its data center chipset opportunity is estimated at $1.5 billion.<figure class="image"><a href="https://stocktwits.com/symbol/RMBS"><img style="aspect-ratio:631/138;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/rmbs_sentiment_5078361ebc.png" alt="rmbs-sentiment.png" width="631" height="138"></a><figcaption>RMBS sentiment and message volume November 26, 2024, as of 10:30 am ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits platform, retailers turned ‘bullish’ (67/100) from a ‘neutral’ disposition a day ago, with message volume rising to ‘high’ level.At last check, Rambus was up 3.27% to $58.75.For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;Related Link:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/zoom-video-reports-beat-and-raise-q3-2025/cJIWZvyRgq">Zoom Video Stock Slumps Despite Beat-and-Raise Q3 But Retail Stays Connected</a>

Rambus shares have underperformed the broader market and the semiconductor industry this year.

Rambus Stock Powers Up After Memory Chipmaker Snags A Bullish Rating: Retail Upbeat

Rambus’ technology and IP is central to the artificial intelligence-driven performance increase in data centers, said Baird analyst Tristan Gerra.

Expectations are muted as Bath &amp; Body Works, Inc. (<a class="mention" data-mention="$BBWI" data-symbol-id="BBWI" href="https://stocktwits.com/symbol/BBWI" target="_blank">$BBWI</a>), a retailer of personal care and home fragrance products, prepares to report its third-quarter results before the market opens on Monday.Analysts, on average, expect the Columbus, Ohio-based company to report third-quarter adjusted earnings per share (EPS) of $0.47 on net sales of $1.58 billion. This compares to the year-ago numbers of $0.48 and $1.56 billion, respectively. The company guided to flat to a 2.5% increase in net sales, translating to $1.56-$1.6 billion.&nbsp;Ahead of the results, Citigroup said it expects above-consensus adjusted EPS due to a slightly stronger gross margin and lower spending, the Fly&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://thefly.com/news.php?symbol=BBWI">reported.</a> While conceding that the third quarter was another difficult quarter to drive sales, due to consumers remaining price-sensitive and the lack of big promotions to drive traffic, the firm said the second-half guidance is conservative enough.&nbsp;Citi believes that the fourth quarter is the best opportunity for the company to deliver upside to sales guidance this year. The firm has a Neutral rating and $35 price target for the stock. The risk/reward is skewed positive, going into the print, it said.Last week, JPMorgan analysts reduced its price target for the shares from $39 to $35.In early November, Bath &amp; Body Works announced a regular quarterly cash dividend of $0.20, payable on Dec. 6, to shareholders at the close of business on Nov. 22.The running quarter’s guidance is important, as it encompassed the holiday season. The forecast for this year’s industry-wide holiday sales is bright, with Bain &amp; Company<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bain.com/insights/2024-holiday-shopping-inside-latest-retail-sales-snap-chart/"> noting</a> a 5.4% year-on-year increase in October compared to September's 3.1% growth.&nbsp;"Santa’s sleigh has kicked into high gear for the start of the season," the firm said. Online sales grew 9.4%, in line with expectations, while in-store sales climbed a better-than-expected 4%, it added.Bath &amp; Body Works currently expects full-year net sales to fall by 2%-4%, with the 53rd week in 2023 representing a 100-basis-point headwind, and adjusted EPS of $3.02-$3.26.&nbsp;Bath &amp; Body Works shares have fallen about 27.33% for the year-to-date period.The average analysts’&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.tipranks.com/stocks/bbwi/forecast">price target&nbsp;</a>for Bath &amp; Body Works stock is $41.20, suggesting roughly 34% upside potential.<figure class="image"><a href="https://stocktwits.com/symbol/BBWI"><img style="aspect-ratio:637/130;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/bbwi_sentiment_064b8def79.png" alt="bbwi-sentiment.png" width="637" height="130"></a><figcaption>BBWI sentiment and message volume November 24, 2024, as of 9:40 pm ET | Source:&nbsp;Stocktwits</figcaption></figure>On Stocktwits, retail sentiment was ‘neutral’ (49/100), a deterioration from the ‘bullish’ mood that prevailed a day ago, while message volume was ‘normal.’The stock ended Friday’s session up 0.52% at $30.71.For updates and corrections email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/govx-siga-ebs-cmrx-stocks-gain-who-declares-who-public-health-emergency/cJId4JgRge">GeoVax, SIGA Jump After WHO Extends Mpox Public Emergency Status: Here’s What Retail Thinks</a>

The holiday quarter got off to a promising start, with a strong October, going by Bain & Co.’s estimates

Bath & Body Works Analyst Cautious Ahead Of Q3 Print: Retail Sentiment Deflates

Price-sensitive consumers and a lack of big promotional drive dampen outlook for Bath & Body Works’ third quarter, Citi said.

Shares of Anavex Life Sciences Corp. ($AVXL) defied the broader market weakness and rallied on Thursday following a clinical trial readout.New York-based Anavex announced new data from the Phase 2b/3 study of its investigational drug candidate blarcamesin, administered as an once-daily oral formulation, demonstrating pre-specified clinical efficacy in people with early Alzheimer’s disease.&nbsp;The drug candidate, codenamed ANAVEX 2-73 worked through upstream activation of SIGMAR1, which is an integral membrane protein.Analysis of Phase 2b/3 data showed that over 48 weeks, blarcamesine&nbsp;significantly slowed clinical progression by 36.3% in the primary endpoint - Alzheimer’s Disease Assessment Scale-Cognitive 13-item, or ADAS-Cog13, scale, in the intention-to-treat&nbsp;analysis, the neurology-focused small-cap biopharma said.&nbsp;Juan Carlos Lopez-Talavera, Head of R&amp;D at Anavex, said, “The advantage of blarcamesine is that it is a small oral molecule that exerts clinical benefits on cognition and neurodegeneration and could be appealing because of its route of administration and good comparative safety profile.”The company said it is on track for regulatory submission of blarcamesine in Europe in the fourth quarter.The data was presented at the Clinical Trials on Alzheimer’s Disease (CTAD) conference, being held in Madrid, Spain.Retail sentiment&nbsp;on Stocktwits has brightened following the data release,&nbsp;making&nbsp;Anavex stock the sixth-most trending&nbsp;ticker on Stocktwits.<figure class="image"><a href="https://stocktwits.com/symbol/AVXL"><img style="aspect-ratio:627/142;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/avxl_sentiment_b45388096b.png" alt="avxl-sentiment.png" width="627" height="142"></a><figcaption>AVXL sentiment and message volume October 31, 2024, as of 2:45 am ET | Source:&nbsp;Stocktwits</figcaption></figure>The&nbsp;sentiment meter trended in the “extremely bullish” (95/100)&nbsp;territory, improving from a “neutral” position a day ago, with message volume spiking to “extremely high.”One Stocktwits user&nbsp;sees scope for further upside in the near term. While noting that the short interest in the stock is 21%,&nbsp;the user said a short squeeze-fueled rally could materialize if the European Medicines Agency accepts the regulatory application for&nbsp;blarcamesine.<stembedurl>https://stocktwits.com/badprecog/message/590798832</stembedurl>As of 2:45 pm ET, Anavex shares rallied 16.29% to $6.64, having pulled back from an intraday high of $7.37. The stock has crossed the $7 threshold for the first time this year.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-to-report-q4-results-after-the-closing-bell-on-thursday/cJ2C2TSRBB">Apple Stock Slips Ahead Of Q4 Results As Analyst Loses Sleep Over Guidance: Retail Mood Stays Sour</a>For updates and corrections email <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com</a>&nbsp;

Anavex plans to file regulatory application for its Alzheimer's drug candidate in Europe.

Anavex Life Sciences Stock Spikes On Late-Stage Alzheimer’s Drug Trial Data, Retail Mood Upbeat

Anavex' once-daily drug candidate demonstrated pre-specified clinical efficacy in people with early Alzheimer’s disease. 

Shares of telehealth company Hims &amp; Hers Health Inc. (<a class="mention" data-mention="$HIMS" data-symbol-id="HIMS" href="https://stocktwits.com/symbol/HIMS" target="_blank">$HIMS</a>) fell over 8% pre-market on Thursday following a key update from the federal government on weight-loss drug supply.Late Wednesday, the U.S. Food and Drug Administration <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize">announced</a> that Eli Lilly’s popular weight-loss and diabetes drugs, Mounjaro and Zepbound, are no longer in shortage after a two-year period where supply couldn’t meet skyrocketing demand.Both medications, which trigger the hormone GLP-1 to help curb appetite, are now available to meet projected national needs, according to the agency.Investors worry that the update could pose a headwind for telehealth companies like Hims &amp; Hers, which have capitalized on the shortages by offering compounded versions of GLP-1 drugs.These alternatives, produced by FDA-registered outsourcing facilities, are sold to customers unable to access originals such as Novo Nordisk’s (NVO) Wegovy or Lilly’s Zepbound.Under U.S. law, telehealth platforms are only allowed to manufacture these copycat drugs when the branded originals are in short supply.<figure class="image"><a href="https://stocktwits.com/symbol/HIMS"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HIMS_sentiment_and_message_volume_Oct_3_pre_market_bdee8c8ba8.png" alt="HIMS sentiment and message volume Oct 3 pre-market" width="1314" height="320"></a><figcaption>HIMS sentiment and message volume Oct 3 pre-market</figcaption></figure>Still, retail sentiment for Hims &amp; Hers remained resilient on Stocktwits, where the ticker held a ‘bullish’ score (74/100) early Thursday.“It’s going to take a while for the market to realize this is not just a semaglutide company,” wrote one user, while another pointed out that Hims &amp; Hers never sold a compounded version of Tirzepatide (Lilly’s drug).<stembedurl>https://stocktwits.com/Hkaz34/message/587849299</stembedurl><stembedurl>https://stocktwits.com/BestRegards/message/587866562</stembedurl>Citi analysts pointed out that Hims &amp; Hers won’t be directly affected by the FDA’s decision, as it compounds semaglutide, the key ingredient in Novo Nordisk’s rival weight-loss drug, which is still on the FDA’s shortage list.&nbsp;However, they cautioned that the FDA’s announcement constrains Hims &amp; Hers's future total addressable market and "portend[s] a faster-than-anticipated resolution to shortages."&nbsp;Hims &amp; Hers is best known for selling treatments like hair-loss products and sexual-health medications like Viagra and Cialis.The company recently entered the weight-loss space as GLP-1 drugs gained popularity, offering compounded versions with the same active ingredient as Novo Nordisk’s Wegovy and Ozempic.In May, the company said its weight-loss business is expected to surpass $100 million in revenue by the end of 2025. This projection did not include the revenue potential of GLP-1 drugs, which could further bolster the company’s growth.Some analysts <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-slides-after-eli-lilly-zepbound-discount/c7wEdA9Rco">have noted</a> that Hims &amp; Hers is growing at over 40% annually, even without significant contributions from these drugs.HIMS stock has nearly doubled in value this year, although Thursday’s pre-market drop reflects the market’s ongoing sensitivity to developments in the GLP-1 space.Editor's note: This article was updated with Citi's note on the potential impact of the FDA's statement on Hims &amp; Hers' business and addressable market.Read next: <a href="https://stocktwits.com/news-articles/markets/equity/nkla-stock-surges-on-q3-deliveries/cJcGll6R3o">Nikola Stock Thunders Ahead After Impressive Q3 Electric Truck Deliveries, Attracts Retail Spotlight</a>For updates and corrections, email <a href="mailto:newsroom@stocktwits.com">newsroom@stocktwits.com.</a>

The move by Lilly is seen as a significant challenge to GLP-1 compounders, including Hims & Hers, which recently entered the weight-loss drug market. 

Hims & Hers Stock Slides After FDA Says Eli Lilly’s Weight-Loss Drug No Longer In Shortage, But Retail Shrugs Off Worries

Under U.S. law, telehealth platforms are only allowed to manufacture copycat weight-loss drugs when the branded originals are in short supply. 

Shares of telehealth company Hims &amp; Hers Health Inc. (HIMS) fell over 5% on Tuesday following <a href="https://stocktwits.com/news/markets/equity/eli-lilly-releases-single-dose-vials-of-weight-loss-drug-zepbound/c7wEcbCRcn">news</a> that Eli Lilly &amp; Co. (LLY) is now selling single-dose vials of its popular weight-loss drug Zepbound at a steep discount.Lilly’s Zepbound vials, priced at $399 per month, represent a 50% or greater discount compared to other incretin or GLP-1 medicines for obesity, as the company attempts to address ongoing supply shortages.The move by Lilly is seen as a significant challenge to GLP-1 compounders, including Hims &amp; Hers, which recently entered the weight-loss drug market.Citi analyst Daniel Grosslight described Lilly’s pricing strategy as a "shot across the bow" for compounders, emphasizing the company's efforts to protect patients from counterfeit or unsafe knock-off versions of the drug.Despite the potential threat from Lilly, analysts remain cautiously optimistic about Hims &amp; Hers' prospects. Needham, which recently initiated coverage of HIMS with a ‘Buy’ rating and a $24 price target, acknowledged the increased volatility associated with the company’s GLP-1 offerings but believes that the impact will ultimately be more positive than negative.Needham said Hims &amp; Hers continues to grow at over 40% annually, even without significant contributions from GLP-1 drugs, boasting over $1 billion in revenue with multiple growth opportunities.<figure class="image"><a href="https://stocktwits.com/symbol/HIMS"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/HIMS_sentiment_and_message_volume_Aug_27_11a0edd9ae.png" alt="HIMS sentiment and message volume Aug 27.png" width="1310" height="316"></a><figcaption>HIMS sentiment and message volume Aug 27</figcaption></figure>On Stocktwits, retail sentiment for HIMS shifted from ‘bearish’ to ‘neutral’ (53/100), with several watchers expressing confidence in the company's long-term growth potential beyond the GLP-1 segment.<stembedurl>https://stocktwits.com/Robinhoodboys/message/584240092</stembedurl>One user pointed out that GLP-1 drugs represent less than 10% of Hims &amp; Hers’ entire drug portfolio, highlighting the company’s diversified product mix.<stembedurl>https://stocktwits.com/ThinkVest/message/584245377</stembedurl>Earlier this month, Hims revealed it was set to buy a U.S.-based compounding pharmacy for approximately $31 million, in line with its strategy of offering copycat versions of popular weight-loss drugs, including those from Novo Nordisk (NVO).Despite the challenges posed by larger competitors like Lilly, Hims &amp; Hers’ strong Q2 performance, which exceeded Wall Street expectations, showed the beat was driven by surging demand for its weight-loss medicines.The company also raised its 2024 sales forecast to a range of $1.37 billion to $1.40 billion (from an earlier guidance of $1.20 billion to $1.23 billion), signaling confidence in its continued growth and market presence.Read Next: <a href="https://stocktwits.com/news/markets/equity/cava-stock-falls-after-key-insiders-sell-shares/c7wEcRaRcF">Cava Stock Plunges As CEO, Key Stakeholders Offload Shares Amid Record Highs: Is Retail Mood Souring?</a>&nbsp;&nbsp; &nbsp;

HIMS Stock Slides After Eli Lilly’s Discounted Single-Dose Zepbound Offering: Retail Investors Unfazed

Wall Street remains cautiously optimistic about Hims & Hers' prospects, with one analyst saying it continues to grow at over 40% annually even without significant contributions from GLP-1 drugs

Despite the potential threat from Lilly, Wall Street remains cautiously optimistic about Hims & Hers' prospects, with one analyst saying it continues to grow at over 40% annually even without significant contributions from GLP-1 drugs


Shares of fast-casual Mediterranean chain Cava Group (CAVA) dropped over 8% in pre-market trading on Tuesday, after closing at a record high in the previous session. &nbsp;The decline comes in response to an SEC filing that revealed key shareholders and top executives have been offloading significant portions of their holdings in the company.Artal International S.C.A., a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million. This sale comes over and above the 5.55 million shares that Artal already sold in the past three months.The move by Artal signals a potential shift in sentiment among early investors who have benefited from Cava’s meteoric rise since its IPO.<stembedurl>https://stocktwits.com/HeisenbergCap/message/584223663</stembedurl>Cava's leadership has also been cashing in on the company’s recent success. CEO Brett Schulman exercised his option to sell 201,504 shares, netting $24.9 million. Founder and Chief Concept Officer Ted Xenohristos also sold 98,490 shares, earning $12.4 million. Furthermore, three other directors collectively sold 11,500 shares.<stembedurl>https://stocktwits.com/mpier/message/584236225</stembedurl>On Stocktwits, retail sentiment stayed in the ‘neutral’ zone (52/100), with message volume surging, as watchers digested the development.<figure class="image"><a href="https://stocktwits.com/symbol/CAVA"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CAVA_sentiment_and_message_volume_Aug_27_premarket_0f309e0c1e.png" alt="CAVA sentiment and message volume Aug 27 premarket.png" width="1310" height="316"></a><figcaption>CAVA sentiment and message volume Aug 27 premarket</figcaption></figure>Cava has been a stand-out performer in the restaurant sector. Since its market debut in June 2023, the stock has soared nearly 230%, driven by a series of earnings beats, impressive same-store sales growth, and the successful launch of new menu items.Earlier this month, Cava reported better-than-expected Q2 results for 2024 and raised its full-year guidance.However, concerns about the company’s valuation have begun to surface. Cava’s price-to-earnings (P/E) ratio currently stands at an eye-popping 345.89, far exceeding that of industry giants like Chipotle Mexican Grill (53.65) and McDonald's Corp (25.26).&nbsp;Read Next: <a href="https://stocktwits.com/news/markets/equity/pzza-stock-rises-on-takeover-speculation/c7w36O5RcN">Papa John’s Stock Rises, Retail Buzz Grows As Analyst Note Sparks Takeover Speculations</a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;

Cava's leadership has also been cashing in on the company’s recent success. 

Cava Stock Plunges As CEO, Key Stakeholders Offload Shares Amid Record Highs: Is Retail Mood Souring?

Artal International, a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million on Monday.

CAVA Stock Topples From Record High On Insider Sales: Is Retail Mood Souring?

Artal International, a 10% stakeholder in Cava, sold six million shares of the firm worth $732 million on Monday.


Shares of fast-casual Mediterranean chain CAVA Inc. (CAVA) saw the highest jump in new retail followers on Stocktwits over the past 24 hours on Thursday, despite ending the session in the red due to profit-booking.Message volume related to the stock surged more than 575% to reach ‘extremely high’ (92/100) levels, as watchers eagerly discussed the company’s Q2 results, which comfortably beat Wall Street estimates on revenue and profit.Same-store sales grew by an impressive 14.4%, exceeding most expectations, while traffic increased by 9.5% during the quarter. This suggests that the restaurant chain is reportedly outperforming many of its peers in a challenging economic environment with cost-conscious consumers.The company highlighted that its grilled steak offering provided customers with "another reason to visit Cava and come back more often." Additionally, CAVA raised its full-year outlook for same-store sales, new location openings, and adjusted profit.At least four Wall Street brokerages have raised their price targets for CAVA, with Baird setting the highest at $125—representing more than a 12% upside from current levels. However, Barclays is the only brokerage so far with a target below current levels, at $95.Despite the stock's near-9% jump before the bell on Friday, retail sentiment on Stocktwits remained 'bearish' (41/100), though it showed slight improvement from the previous day.<figure class="image"><a href="https://stocktwits.com/symbol/CAVA"><img style="aspect-ratio:1310/316;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CAVA_sentiment_and_message_volume_Aug_23_premarket_c017101953.png" alt="CAVA sentiment and message volume Aug 23 premarket.png" width="1310" height="316"></a><figcaption>CAVA sentiment and message volume Aug 23 premarket</figcaption></figure>Several pessimistic observers expressed concerns about the stock’s valuation.“$CAVA very overvalued imo and fake pump so big boys can unload to bag holders (retail). Caution,” warned one user.<stembedurl>https://stocktwits.com/stockswnoiz/message/583908678</stembedurl>“$CAVA Forward P/E is 300!+. That’s crazy!,” posted another bearish user.<stembedurl>https://stocktwits.com/ShortyMcShorterson/message/583891113</stembedurl>CAVA’s current market cap stands at $11.63 billion, with its valuation having skyrocketed over 167% since its stellar market debut in June 2023.The stock’s current price-to-earnings (P/E) ratio is 400.86, which significantly exceeds that of Chipotle Mexican Grill (CMG) at 52.38 and Domino’s Pizza Inc. (DPZ) at 25.59.Wedbush Securities believes CAVA is positioned to sustain positive transaction growth and gain market share over the long term, even relative to its growth peers, adding that the stock's premium valuation would be justifiable.But on Retail Street, investors are just not able to digest these views for now.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

The company highlighted that its grilled steak offering provided customers with "another reason to visit Cava and come back more often."

CAVA Stock’s Retail Following Jumps Most After Upbeat Q2 Results, But Sentiment ‘Bearish’

The restaurant chain is reaping the rewards of its grilled steak offering, which has been hit with customers. Shares are trading at all-time highs just 14 months after going public, but retail sentiment is still repressed.

CAVA Stock’s Retail Following Jumps Most After Upbeat Q2 Results

The restaurant chain is reaping the rewards of its grilled steak offering, which has been hit with customers. Shares are trading at all-time highs just 14 months after going public, but retail sentiment is still repressed.


BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

IWV
BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IWV News

IWV BlackRock Institutional Trust Company N.A. - iShares Russell 3000 ETF